OBJECTIVE: Preclinical studies have shown that low-dose methylene blue increases mitochondrial cytochrome oxidase activity in the brain and improves memory retention after learning tasks, including fear extinction. The authors report on the first controlled experiment to examine the memory-enhancing effects of posttraining methylene blue administration on retention of fear extinction and contextual memory following fear extinction training. METHOD:Adult participants displaying marked claustrophobic fear were randomly assigned to double-blind administration of 260 mg of methylene blue (N=23) or administration of placebo (N=19) immediately following six 5-minute extinction trials in an enclosed chamber. Retesting occurred 1 month later to assess fear renewal as indexed by peak fear during exposure to a nontraining chamber, with the prediction that the effects of methylene blue would vary as a function of fear reduction achieved during extinction training. Incidental contextual memory was assessed 1 and 30 days after training to assess the cognitive-enhancing effects of methylene blue independent of its effects on fear attenuation. RESULTS: Consistent with predictions, participants displaying low end fear posttraining showed significantly less fear at the 1-month follow-up if they received methylene blue posttraining compared with placebo. In contrast, participants displaying moderate to high levels of posttraining fear tended to fare worse at the follow-up if they received methylene blue posttraining. Methylene blue's enhancement of contextual memory was unrelated to initial or posttraining claustrophobic fear. CONCLUSIONS:Methylene blue enhances memory and the retention of fear extinction when administered after a successful exposure session but may have a deleterious effect on extinction when administered after an unsuccessful exposure session.
RCT Entities:
OBJECTIVE: Preclinical studies have shown that low-dose methylene blue increases mitochondrial cytochrome oxidase activity in the brain and improves memory retention after learning tasks, including fear extinction. The authors report on the first controlled experiment to examine the memory-enhancing effects of posttraining methylene blue administration on retention of fear extinction and contextual memory following fear extinction training. METHOD: Adult participants displaying marked claustrophobic fear were randomly assigned to double-blind administration of 260 mg of methylene blue (N=23) or administration of placebo (N=19) immediately following six 5-minute extinction trials in an enclosed chamber. Retesting occurred 1 month later to assess fear renewal as indexed by peak fear during exposure to a nontraining chamber, with the prediction that the effects of methylene blue would vary as a function of fear reduction achieved during extinction training. Incidental contextual memory was assessed 1 and 30 days after training to assess the cognitive-enhancing effects of methylene blue independent of its effects on fear attenuation. RESULTS: Consistent with predictions, participants displaying low end fear posttraining showed significantly less fear at the 1-month follow-up if they received methylene blue posttraining compared with placebo. In contrast, participants displaying moderate to high levels of posttraining fear tended to fare worse at the follow-up if they received methylene blue posttraining. Methylene blue's enhancement of contextual memory was unrelated to initial or posttraining claustrophobic fear. CONCLUSIONS:Methylene blue enhances memory and the retention of fear extinction when administered after a successful exposure session but may have a deleterious effect on extinction when administered after an unsuccessful exposure session.
Authors: Kathryn M Wrubel; Douglas Barrett; Jason Shumake; S Elizabeth Johnson; F Gonzalez-Lima Journal: Neurobiol Learn Mem Date: 2006-10-02 Impact factor: 2.877
Authors: Leila M Soravia; Markus Heinrichs; Amanda Aerni; Caroline Maroni; Gustav Schelling; Ulrike Ehlert; Benno Roozendaal; Dominique J-F de Quervain Journal: Proc Natl Acad Sci U S A Date: 2006-03-27 Impact factor: 11.205
Authors: Eric A Storch; Lisa J Merlo; Michael Bengtson; Tanya K Murphy; Mark H Lewis; Mark C Yang; Marni L Jacob; Michael Larson; Adam Hirsh; Melanie Fernandez; Gary R Geffken; Wayne K Goodman Journal: Int Clin Psychopharmacol Date: 2007-07 Impact factor: 1.659
Authors: Matt G Kushner; Suck Won Kim; Christopher Donahue; Paul Thuras; David Adson; Michael Kotlyar; James McCabe; Jillian Peterson; Edna B Foa Journal: Biol Psychiatry Date: 2007-06-22 Impact factor: 13.382
Authors: Stefan G Hofmann; Alicia E Meuret; Jasper A J Smits; Naomi M Simon; Mark H Pollack; Katherine Eisenmenger; Michael Shiekh; Michael W Otto Journal: Arch Gen Psychiatry Date: 2006-03
Authors: Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack Journal: Biol Psychiatry Date: 2015-09-25 Impact factor: 13.382
Authors: Pavel Rodriguez; Wei Zhou; Douglas W Barrett; Wilson Altmeyer; Juan E Gutierrez; Jinqi Li; Jack L Lancaster; Francisco Gonzalez-Lima; Timothy Q Duong Journal: Radiology Date: 2016-06-28 Impact factor: 11.105
Authors: Bina Tariq; Sorina R Simon; Walmari Pilz; Andra Maxim; Bernd Kremer; Laura W J Baijens Journal: Eur Arch Otorhinolaryngol Date: 2021-01-02 Impact factor: 2.503
Authors: Pavel Rodriguez; Amar P Singh; Kristen E Malloy; Wei Zhou; Douglas W Barrett; Crystal G Franklin; Wilson B Altmeyer; Juan E Gutierrez; Jinqi Li; Betty L Heyl; Jack L Lancaster; F Gonzalez-Lima; Timothy Q Duong Journal: Brain Imaging Behav Date: 2017-06 Impact factor: 3.978
Authors: Seth Davin Norrholm; Tanja Jovanovic; Maryrose Gerardi; Kathryn G Breazeale; Matthew Price; Michael Davis; Erica Duncan; Kerry J Ressler; Bekh Bradley; Albert Rizzo; Peter W Tuerk; Barbara O Rothbaum Journal: Behav Res Ther Date: 2016-05-07